Myasthenia gravis concurrent with Parkinson's disease in a Spanish cohort. Causation or correlation?
- PMID: 38300400
- DOI: 10.1007/s10072-024-07349-3
Myasthenia gravis concurrent with Parkinson's disease in a Spanish cohort. Causation or correlation?
Abstract
Background: Comorbidity between myasthenia gravis (MG) and other autoimmune diseases is well-documented. However, concurrent MG and Parkinson's disease (PD) have rarely been described. This concurrence has mostly been considered coincidental in cases reported to date.
Material/methods: We characterized patients with concurrent MG and PD within a cohort of 631 MG patients by gender, age, MGFA class, quantitative MG score at diagnosis, UPDRS score at diagnosis, and the DaTSCAN uptake pattern, to determine the frequency and the phenotype of individuals with these two concurrent entities. Meta-analysis of cases in the literature was used for comparison with our series.
Results: Eighteen cases were identified in which the two diseases were concurrent. The major characteristics of the phenotype are male prevalence, late-onset MG, and frequent initial symptoms of dropped head and oculobulbar involvement. DAT confirmed reduced bilateral uptake in eleven patients and reduced unilateral uptake in the others.
Conclusions: To our knowledge, this is the largest reported series of concurrent MG and PD. This concurrence is more common than expected (2.85%). Either MG or PD may appear first. We found no iatrogenic relationship for the order of appearance. The overlapping of symptoms sometimes leads physicians to overlook the second disease, instead viewing it as a deterioration of the first. This study describes patients with well-documented diagnoses of both MG and PD, thus providing further indications of a shared etiology of these two diseases. Prospective studies including genetic, immunological, and environmental analysis are necessary to identify possible common pathogenic mechanisms.
Keywords: Comorbidity; DaT Scan; Epidemiology; Head drop; Late-onset myasthenia gravis; Parkinson’s disease.
© 2024. Fondazione Società Italiana di Neurologia.
Similar articles
-
Myasthenia Gravis crossing Parkinson's disease: a 20 year study from single Italian center.Int J Neurosci. 2024 May;134(5):429-435. doi: 10.1080/00207454.2022.2107517. Epub 2022 Sep 4. Int J Neurosci. 2024. PMID: 35917141
-
Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort.J Neurol Sci. 2016 Jan 15;360:110-4. doi: 10.1016/j.jns.2015.11.049. Epub 2015 Nov 27. J Neurol Sci. 2016. PMID: 26723985
-
Is it just a coincidence? Three new cases of Myasthenia Gravis associated with Parkinson's disease.Parkinsonism Relat Disord. 2016 Jul;28:166-8. doi: 10.1016/j.parkreldis.2016.04.005. Epub 2016 Apr 12. Parkinsonism Relat Disord. 2016. PMID: 27079256 No abstract available.
-
Patients with Parkinson's Disease and Myasthenia Gravis-A Report of Three New Cases and Review of the Literature.Medicina (Kaunas). 2019 Dec 23;56(1):5. doi: 10.3390/medicina56010005. Medicina (Kaunas). 2019. PMID: 31878081 Free PMC article. Review.
-
Double vision in Parkinson's Disease: a systematic review.Neurol Neurochir Pol. 2020;54(6):502-507. doi: 10.5603/PJNNS.a2020.0092. Epub 2020 Dec 10. Neurol Neurochir Pol. 2020. PMID: 33300115
Cited by
-
Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence.Int J Mol Sci. 2025 Mar 24;26(7):2942. doi: 10.3390/ijms26072942. Int J Mol Sci. 2025. PMID: 40243562 Free PMC article. Review.
-
Dropped Head Syndrome: The Importance of Neurophysiology in Distinguishing Myasthenia Gravis from Parkinson's Disease.Biomedicines. 2024 Aug 12;12(8):1833. doi: 10.3390/biomedicines12081833. Biomedicines. 2024. PMID: 39200297 Free PMC article.
References
-
- Ueno S, Takahashi M, Kajiyama K, Okahisa N, Hazama T, Yorifuji S, Tarui S (1987) Parkinson’s disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology 37(5):832–833. https://doi.org/10.1212/wnl.37.5.832 - DOI - PubMed
-
- Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, Shohaimi S, Mohammadi M (2021) Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med 19(1):516. https://doi.org/10.1186/s12967-021-03185-7 - DOI - PubMed - PMC
-
- Somnier FE (2005) Increasing incidence of late-onset anti–AChR antibody–seropositive myasthenia gravis. Neurology 65(6):928–930. https://doi.org/10.1212/01.wnl.0000176067.32186.a3 - DOI - PubMed
-
- Alkhawajah NM, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve 48(5):705–710. https://doi.org/10.1002/mus.23964 - DOI - PubMed
-
- O’Shea SA, Shih LC (2023) Global epidemiology of movement disorders: rare or underdiagnosed? Semin Neurol 43(1):4–16. https://doi.org/10.1055/s-0043-1764140 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical